Nasal spray 0.1% in the form of a clear, odorless, clear solution.
– acute respiratory diseases with rhinitis (runny nose) symptoms
– allergic rhinitis (hay fever)
– otitis media (to reduce nasal mucosa swelling in the patient for surgery).
– arterial hypertension
– severe atherosclerosis
– atrophic rhinitis
– thyrotoxicosis sardlkp – children’s age up to 2 years (for nasal spray 0.05%)
– hypersensitivity to the components of the drug.
Caution is advised to use the drug for diabetes mellitus, ischemic heart disease.
Before use, the nasal passages must be cleaned.
Rinomaris should not be used for a long time, for example, in chronic rhinitis.
Effect on the ability to drive vehicles and control mechanisms
Xylometazoline in doses exceeding the recommended, may affect the ability to drive vehicles or equipment.
xylometazoline hydrochloride 10 mg
Excipients: Adriatic Sea water – 2.4162 g, potassium dihydrogen phosphate – 4.9 mg, purified water – up to 10 ml.
Dosage and administration of
Rinomaris nasal spray, dosage 0.05%
For children aged 2 to 6 years: 1 injection into each nostril 1-2 times / day.
Children over 6 years of age: 1 injection into each nostril 2-3 times / day.
Rinomaris nasal spray, dosed 0.1%
Children over 6 years and adults: 1 injection in each nostril 2-3 times / day.
The drug should not be used more often 4 times / day. Course duration – no more than 5-7 days.
From the respiratory system: with frequent and / or prolonged use – irritation and / or dryness of the mucous membrane of the nasopharynx, burning, tingling, sneezing, hypersecretion, swelling of the nasal mucosa.
From the cardiovascular system: palpitations, tachycardia, arrhythmias, increased blood pressure.
From the nervous system: headache, insomnia with prolonged use in high doses – depression.
Other: vomiting, visual impairment.
Rinomaris is incompatible with MAO inhibitors and tricyclic antidepressants.
Symptoms: increased side effects.
Treatment: symptomatic treatment.
The product should be stored out of the reach of children at a temperature not exceeding 25 ° C.
Conditions of release from drugstores
Jadran-Galensky Laboratories a.o., Croatia